slides · global inventory
Evidence Matrix
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 335
Current window 241-270
Pages 12
Rows per page 30
Framework
241-270 of 335
04
The slide uses a citation from Schroeder (2007) to validate the claim.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Uses a simple Venn-like diagram to illustrate the small subset of successful drugs.Absci | Investor Presentation Deck | 26 slides · Absci
Pitch deck Investor relations Beat · Problem StatementLoop · Cost Of Inaction1 hit
26
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
29
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
09
The chart illustrates the correlation between Cyno and Human half-life, showing YTE mAbs (Spyre's approach) outperforming WT mAbs.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
11
The Venn diagram shows the intersection of genetic targets (TL1A, IL-23, a4b7). The bar chart compares 'All-comers' vs 'CDx+' (companion diagnostic positive) patient groups for two drugs (PRA023 and RVT-3101).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
08
The slide uses a survey by BCG to validate brand strength and identify a specific operational bottleneck (inventory availability).Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The slide showcases a specific case study of project finance as a proof point for business model scalability and de-risking.Allego | Investor Presentation Deck | 50 slides · Allego
Pitch deck Investor relations 1 hit
36
Includes three news clippings as evidence of recent deal activity.Altair US LLC | Activist Presentation Deck | 38 slides · Altair US, LLC
Activist deck Activist investor Beat · Solution1 hit
17
Includes Kaplan-Meier survival curve and comparative efficacy tables.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
35
Includes qualitative feedback from KOLs and healthcare providers regarding clinical utility and patient selection.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
13
Kaplan-Meier survival curves showing primary (2020) and updated (2023) analysis results.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
11
The slide uses a dual-panel layout to compare animal model data (left) with human Phase 1 clinical trial data (right).ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
13
Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
34
The chart highlights a statistically significant difference between CBD and Placebo groups during the speaking phase.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
16
Includes detailed scientific citations and specific cohort dosing strategies.Cabaletta Bio | Investor Presentation Deck | 23 slides · Cabaletta Bio
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The table uses a color-coded heatmap to highlight favorable (green) vs unfavorable (pink) characteristics of clinical trial data.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a chevron-based table structure to link disease states to market validation.Enochian Biosciences | Investor Presentation Deck | 39 slides · Enochian BioSciences
Pitch deck Investor relations Beat · Market Size1 hit
06
The slide uses a chevron-based process flow to map disease states to market validation.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
34
Includes RECIST 1.1 criteria reference and specific tumor measurements over time.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
33
The slide uses a combination of donut charts for sample sizes and bar charts for statistical significance, followed by scatter plots to visualize the inverse correlation.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a combination of bar charts and scatter plots to demonstrate the inverse relationship between ABS and TIS.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
28
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
25
Data sourced from Capital IQ; includes specific criteria for transaction selection (market cap < $500M, premiums > 100% marked as NM).ROTH Capital Partners | Investment Banking Pitch Book | 28 slides · Roth Capital Partners
Deck Investment bank Beat · Impact & Next Steps1 hit
20
The slide uses a timeline-like structure to demonstrate historical success.Sarissa Capital | Activist Presentation Deck | 41 slides · Sarissa Capital
Activist deck Activist investor Beat · The StruggleLoop · Voice Of Customer1 hit
27
The slide uses forest plots to compare treatment effects (ampreloxetine vs placebo) across different patient populations (Overall, MSA, PD, PAF).Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · KPI Overview1 hit
17
The slide combines mechanistic biological data (Maun et al.) with clinical trial results (Cahill et al., NEJM) to justify targeting mast cells in severe asthma.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Why NowLoop · Why Now1 hit